President Donald Trump on Wednesday signed into law two bills that mean all pharmacists are now allowed to inform patients of whether they can purchase medicines for less money.
The so-called “gag clauses” previously restricted pharmacists from informing patients of what the new law calls “any differential between the negotiated price of, or copayment or coinsurance for, the drug or biological to the enrollee under the plan and a lower price the individual would pay for the drug or biological if the enrollee obtained the drug without using any health insurance coverage.”
In addition, the Patient Right to Know Drug Prices Act also requires manufacturers to report to the Federal Trade Commission pay-for-delay agreements that could slow biosimilars from entering the market.
The Pharmaceutical Care Management Association (PCMA), which represents pharmacy benefit managers, said it “strongly supports” both laws.
First published here. Regulatory Focus is the flagship online publication of the Regulatory Affairs Professionals Society (RAPS), the largest global organization of and for those involved with the regulation of healthcare and related products, including medical devices, pharmaceuticals, biologics and nutritional products. Email email@example.com for more information.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.Free Subscription